Bloom syndrome is an autosomal recessive disorder associated with mutations in BLM gene encoding protein that belongs to the family of DNA helicases. It is characterized by predisposition to cancer, immunode®ciency, high sensitivity to UV and genomic instability of somatic cells. Here we show physical and functional cooperation between BLM and p53 proteins. Ectopic expression of BLM causes anti-proliferative eect in p53 wild type, but not in p53-de®cient cells; p53-mediated transactivation is attenuated in primary ®broblasts from Bloom syndrome patients. BLM and p53 proteins physically interact in the cells as demonstrated in yeast and mammalian two-hybrid systems; interaction sites are mapped to 237 ± 272 aa residues of BML and 285 ± 340 aa of p53. Ectopic expression of the fragment of wild type BML containing p53-interactive domain suppresses p53-mediated transcription and interferes with p53-mediated growth inhibition. These observations indicate that BLM might be an important component of p53 function and suggest that Bloom Syndrome phenotype may in part be the result of the deregulation of the p53 tumor suppressor pathway. Oncogene (2001) 20, 8276 ± 8280.
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Keywords: Bloom syndrome; BLM protein; p53; interaction; two-hydrid system; transactivation Bloom syndrome results from mutations inactivating BLM gene that encodes a RecQ family DNA helicase (Mohaghegh et al., 2001) . Patients with Bloom syndrome are hypersensitive to UV radiation, suering from sun-sensitive facial erythema, and show predisposition to tumor development (German, 1993) . BLMde®cient cells from such individuals are characterized by a dramatic increase in sister chromatid exchange, chromosome breaks and abnormally high mutation rate (Ellis et al., 1994) . Genomic instability is also associated with de®ciency of the p53 tumor suppressor gene, a key mediator of cellular response to a variety of stresses that is frequently mutated in many dierent types of human cancers (Wallace-Brodeur and Lowe, 1999; Prives and Hall, 1999) . Germ line p53 de®ciency is also associated with inherited disease (Li-Fraumeni syndrome) that has many similarities with the Bloom syndrome (German, 1993; Akashi and Koeer, 1998) . Several dierent mechanisms are involved in p53-mediated control of genomic stability including induction of p53-dependent growth arrest or apoptosis in response to genotoxic stress, modulation of DNA repair machinery, control of accuracy of chromosomal segregation in mytosis, etc.; p53 exerts these functions through physical and functional interaction with numerous cellular proteins (Prives and Hall, 1999) . Potential functional cooperation between BLM and p53 has been suggested by Lu and Lane (1993) , based on their observations of attenuated p53 response in the cells from Bloom syndrome patients. However, there has been no evidence of a mechanistic link between these two proteins.
This work was initiated by two independent observations: (i) dierence in growth suppressive activity of ectopically expressed BLM in two sarcoma cell lines diering in their p53 status (Figure 1a) , and (ii) strong interaction of BML and p53 in yeast two hybrid system con®rmed by co-precipitation of two proteins from mammalian cells (see below). These observations stimulated us to analyse p53-BML interaction in greater detail.
BLM cDNA expressed in mammalian expression vector pBK from CMV promoter was transfected into human osteosarcoma cell lines, Saos2 (p53-de®cient) and U2OS (wild-type p53), along with the insert-free vector. There was a dramatic dierence between two cell lines in their sensitivity to ectopic expression of BLM. While no dierence was found in colony formation between vector and BLM plasmids in p53-negative Saos-2, BLM was clearly growth suppressive in p53-wild type U2OS cells (Figure 1a ). These observations suggested that the growth-inhibitory eect of BLM required the presence of functional wild-type p53.
To con®rm whether BLM-mediated growth suppression is, in fact, p53 dependent, we analysed the eect of p53 suppression on BLM-mediated growth inhibition by BLM-expressing plasmid in a more accurate experimental setup independent of the possible dierences in cell types. A variant of Balb 3T3-derived cell 5 ConA cells plated on 60-mm plates were transfected with 2 mg of retroviral vector plasmid, pBABE-phleo, (Morgenstern et al., 1990) expressing full-length cDNA for human BLM gene and bacterial bleo gene, confering resistance to phleomycin. BLM-expressing plasmid was mixed either with 3 mg of either empty pBABE-puro vector or with the pBABE-puro, expressing GSE56, a potent inhibitor of p53 function (Ossovskaya et al., 1996) . Transfection eciency was estimated by adding GFP-expressing construct into transfection and calculating the proportion of¯uorescent cells as described above. Fifty mg/ml of phleomycin were added 48 h after transfection and numbers of phleomycin resistant colonies were estimated after selection on phleomycin was completed. The results obtained demonstrate that GSE56 highly increased the number of phleomycin-resistant colonies, indicating that BLM-mediated cytotoxicity is indeed p53-dependent ) were fused to the pJG4-5 plasmid were used as preys. Cdk4-pJG4-5 was used as a negative and SV40-pJG4-5 as a positive control. Bait construct expressed p53 cDNA with truncated oligomerization domain in pEG202 vector (83 ± 393 aa). Interaction was detected by yeast growth on galactose leu ± plate and by activation of lacZ on the X-Gal plate. (b) Mapping of BLM-interacting domain in p53 protein. The experiment was done as described above (a). A series of p53-expressing`bait' constructs (shown on top) were tested for interaction with BLM p53-binding fragment (152 ± 500 aa) in`prey' plasmid. Max-pJG4-5 and SV40-pJG4-5 were shown as negative and positive controls, respectively line, ConA, was used (Komarova et al., 1997). The results obtained (see Figure 1b) indicate that colony suppression by BLM-expressing construct was eectively abrogated by a dominant negative p53 mutant, GSE56, thus con®rming that the growth suppressive eect of BLM is p53-mediated.
In parallel, we de®ned BLM protein as a p53 interactor in yeast two-hybrid selection (LexA system, Clontech Laboratories) by screening HeLa cDNA library using truncated human p53 cDNA as bait. A series of bait/prey constructs expressing truncated versions of p53 and BLM were generated (see Figure  2) to de®ne the interacting sites in these two proteins. Analysis of these results allowed us to map interacting domains to 237 ± 272 aa of BLM and 285 ± 340 aa of p53.
Interaction of p53 and BLM detected in the yeast two-hybrid system suggested that these proteins might physically interact in the mammalian cell environment. In fact, p53 and BLM proteins can be co-immunoprecipitated from human cells ectopically co-expressing both proteins (data not shown). However, none of these observations can serve as proof of functionality of p53-BLM interaction: p53 is known to be coprecipitated with numerous proteins in mammalian cell lysates while protein interaction in the two-hybrid system is a rather frequent yeast artifact. We therefore carried out the mammalian two-hybrid assay using Strategene Mammalian Two-Hybrid Assay Kit that allows veri®cation of protein ± protein interaction in the live cell environment. 1 ± 431 aa BLM DNA fragment that showed interaction with p53 in yeast fused with the N-terminal portion of NF-kB tranactivation domain was used in these experiments in combination with the 72 ± 390 aa p53 fragment fused with the Cterminus of NK-kB transactivation domain. Protein ± protein interaction was determined by activation of NF-kB-mediated transcription of a reporter construct with luciferase. A series of constructs were used as controls of speci®city of the studied interaction. The results of a representative experiment are shown in Figure 3 and demonstrates that the pair of BLM-p53 bait/prey plasmids induced activation of the reporter construct, indicative of physical interaction of these two proteins in mammalian cells, resulting in restoration of a transactivator function of NK-kB 4 ± 5 times lower than a positive control p53-SV40 T-ag pair. None of the negative controls, including BLM construct with a frameshift mutation (deletion of the 459 adenosine nucleotide) showed reporter activation higher than background.
p53 is believed to exert its growth suppressive functions through modulation of transcription of a number of p53-response genes, including p21 WAF1/CIP1 (el Deiry et al., 1993) . To directly test the ability of BLM to modulate p53-mediated transcription, p53-de®cient Saos2 cells were transfected with plasmid combinations, including a reporter plasmid expressing chloramphenicol acetyltransferase (CAT) gene from a minimal promoter with p53 binding sites from human p21 gene vector (el Diery et al., 1993) expressing wildtype p53 from CMV promoter and dierent fragments of BLM cDNA in sense or antisense orientation. Sense oriented BLM cDNA stimulated p53-mediated transactivation as judged by a 3 ± 4-fold increase in the levels of CAT activity in comparison to p53-expressing plasmid alone; BLM-expressing plasmid did not activate the p21 WAF/CAT reporter in the absence of p53 (Figure 4a ). Antisense BLM construct had an opposite eect, presumably by interfering with endogenous BLM gene expression. Vectors expressing truncated versions of BLM did not have the activity of a full-length construct. Moreover, a BLM fragment capable of p53 binding had an eect similar to that of antisense construct, presumably through a dominant negative activity. BLM expression did not stimulate transcription of E2F-responsive reporter construct, suggesting that BLM eects are speci®c for p53-inducible promoters (data not shown). Figure 3 Interaction between Bloom protein and p53 monitored by mammalian two hybrid system. BLM cDNA subcloned into pCMV-AD vector and fused with NF-kB transcriptional activation domain. p53 DNA fragment (72 ± 390 aa) was fused in frame to the carboxyl (C) terminus of the GAL4-DNA binding domain (pBD-53) and SV40 large T-antigen (84 ± 708 aa) was fused to the C-terminus of NF-kB p65 activation domain (pAD-SV40T) and then these constructs were used as positive control for protein ± protein interaction assays. TRAF-2,13 (297 ± 503 aa) which do not interact with p53 was used as negative control. Indicated combinations of plasmids (0.2 mg each) were transfected together with the reporter plasmid pFR-Luc (0.25 mg) into 293 or H1299 cell lines and their luciferase activities were monitored in 48 h p53-modulating eects of full-length and truncated p53-binding BLM fragments were con®rmed on endogenous p21 and p53 proteins (Figure 4b ): p53-interacting BLM fragment and antisense BLM construct interfered with p21 activation while fulllength BLM cDNA expression had a stimulatory eect.
Biological signi®cance of this modulating eect was demonstrated by colony assay for growth-suppressing activity of ectopically expressed p53 (Figure 4c) . The results obtained indicate that the construct expressing the fragment of BLM protein, de®ned as p53 interactor in the two-hybrid system, behaves similarly to the dominant negative mutant of p53 in co-transfection experiments.
The results of the above transfection experiments are consistent with the attenuated p53 transactivation typical for the cells from Bloom syndrome patients as demonstrated by comparison of p21-CAT reporter construct transfected into primary ®broblasts diering in their BLM status (Figure 4d ).
In conclusion, we have demonstrated that BLM protein physically and functionally interacts with p53 in cell growth control, presumably by modulating (1), growing on 60-mm plates were co-transfected with 1.5 mg of retroviral vector plasmid pPS-p53-hygro (Garkavtsev et al., 1998) together with 3.5 mg of either pBLM1 (154 ± 500 aa) or pBLM2 (501 ± 1418 aa) and 1 mg of pL(GFP)SN vector expressing enhanced green¯uorescent protein to monitor the ecacy of transfection. Two hundred mg/ml of hygromycin were added 48 h after transfection and the numbers of growing colonies were estimated 14 days of hygromycin selection conferred by p53-expressing vector. Parallel plates were treated similarly, but instead of the construct expressing the fragments of BLM, were used either`empty' pBK vector (vec2) or retroviral vector pL(GSE56)SN, expressing GSE56. Transfection eciencies were estimated by the number of uorescent GFP-expressing cells 48 h after transfection and the results of colony assay were normalized accordingly. Colony numbers are presented in comparison with the plates transfected with a mixture of two`empty' vectors (vec1+vec2). (d) Primary cultures of BLM-de®cient and wild type ®broblasts were co-transfected with 6 mg of p21/WAF CAT reported plasmid together with 2 mg pQB125 vector expressing enhanced green¯uorescent protein to monitor the ecacy of transfection and CAT activity was estimated 24 h post-transfection (stimulating) p53-mediated transactivation. BLM is a member of the RecQ subfamily of DexH box-containing RNA and DNA helicases (Ellis et al., 1995) . p53 has already been shown to interact with another family member, Werner syndrome protein (WRN), that binds p53 through its C-terminus and is involved in induction of p53-dependent apoptosis (Spillare et al., 1999) . Furthermore, when this work was in preparation, Wang et al. (2001) reported about p53-BLM interaction without mapping interacting domains. Werner and Bloom syndromes are inherited diseases characterized by cancer predisposition and genomic instability, both also known to be associated with p53 de®ciency (LiFraumeni syndrome). Deregulation of p53 response in the absence of WRN and BLM p53-cooperating proteins may be the underlying cause of the above phenotypic abnormalities of Werner and Bloom patients. At the same time, not all Bloom and Werner syndrome-associated symptoms could be attributed to p53 since neither premature aging (Werner syndrome) nor high frequency of sister chromatid exchange (Bloom syndrome) are the characteristics of p53 de®ciency.
Although WRN and BLM proteins share a high degree of homology in DEAN helicase domains (Morozov et al., 1997) , their p53-interacting interaction proteins have no detectable similarities. The mechanics of p53 interaction with these two important helicases and how this interaction is translated into deregulated control of genomic stability remains to be understood.
